CRST is working under a SOP-based quality system. The main guidance followed is ICH GCP, with highly skilled professionals in QA and QC positions. All clinical personnel are required to be GCP trained. Internal audits are used to ensure high quality.
CRST’s aim is to provide its customers state-of-the-art solutions based on the most recent scientific knowledge. Our competence stems in part from networking to establish the required expertise and technologies, allowing us to serve all areas of clinical drug research as a single organization.
CRST’s study teams have extensive experience in conducting early-phase clinical trials according to GCP guidelines since 1996. Over the years, we have developed the knowledge and skills to employ flexible study designs and a wide spectrum of surrogate endpoints designed to capture maximal information on the safety and pharmacological effects of the investigated compounds.
Based on close cooperation with the Medical Faculty of the University of Turku and with Turku University Hospital, CRST has direct access to a wide network of clinical specialists in almost all therapy areas.
Clinical study approaches using PET imaging can provide significant benefits in the early development of a drug candidate, including the potential to obtain information on
PET imaging provides information to support the therapeutic and/or diagnostic rationale of your candidate molecule. CRST has a long history of close collaboration with Turku PET Centre (see https://turkupetcentre.fi/) in PET imaging and tracer development projects.